Covid 19 Research using Clinical Trials (Home Page)
Report for D012213: Rheumatic Fever NIH
(Synonyms: Rheumatic Fever)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug627 | Cellectra 2000 Electroporation Wiki | 0.58 |
| drug622 | Cash transfer Wiki | 0.58 |
| drug1151 | GLS-5300 Wiki | 0.41 |
| drug3437 | questionnaire assesment Wiki | 0.26 |
| drug1004 | Enoxaparin Wiki | 0.17 |
There are 3 clinical trials
Clinical Trials
1 Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study
Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.
NCT04353609 Sars-CoV2 Chronic Inflammatory Rheumatism Autoimmune Diseases MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases Autoimmune Diseases
HPO:Autoimmunity
Primary Outcomes
Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death Time: From Baseline up to Day 21 after first symptoms of covid-19
Secondary Outcomes
Measure: Proportion of patients who die from a severe form of covid-19 Time: From Baseline up to Day 21 after first symptoms of covid-19
Measure: Proportion of patients who present an history of diabetes according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2) Time: At the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Asthma according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Hypertension according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cardiac disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of stroke according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cancer according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
2 Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants
Primary Outcomes
Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death Time: From Baseline up to Day 21 after first symptoms of covid-19Secondary Outcomes
Measure: Proportion of patients who die from a severe form of covid-19 Time: From Baseline up to Day 21 after first symptoms of covid-19Measure: Proportion of patients who present an history of diabetes according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2) Time: At the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Asthma according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Hypertension according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cardiac disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of stroke according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cancer according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
A retrospective monocentric study with large active files of patients monitored for rheumatoid arthritis, spondyloarthritis and systemic lupus erythematosus with as main endpoint the morbimortality of Covid-19 in these patients (number of patients hospitalized in conventional units and/or in intensive care and/or deceased). The results will be compared with those of the general population based on the epidemiological data of Covid-19.
NCT04426279 Sars-CoV2 Rheumatoid Arthritis Rheumatic Diseases Other: questionnaire assesment MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases
Primary Outcomes
Description: The diagnosis of Covid-19 is either confirmed by diagnostic test (RT-PCR), or by a physician, or by serology. The results will be compared with those of the general population based on Covid-19 epidemiological data.
Measure: the number of patients with severe Covid-19 who were admitted to a conventional unit and/or an ICU and/or deceased, during the Covid-19 epidemic wave (from March to August 2020) among patients with IRC under IS. Time: At 6 monthsSecondary Outcomes
Measure: Diagnosis of Covid-19 either confirmed by diagnostic test (RT-PCR), or by a physician, or by serology. Time: At 6 monthsMeasure: The number of patients admitted to conventional unit and/or ICU and/or deceased among patients with IRC under IS between the Covid-19 epidemic wave (March to August 2020) and the six-month period preceding it (September to February 2020). Time: At 6 months
Description: Treatment modification will be assessed by the number of weeks of treatment not taken, the number of injections not given, the number of delayed or missed infusions. Among those who have modified or stopped their treatment, the impact on their diseases will be evaluated by the loss of remission, the patient's opinion on the notion of relapse, the increase or initiation of corticosteroid therapy and the substantive change in treatment.
Measure: The number of patients who maintained, modified, or discontinued their treatment. Time: At 6 months3 Mental Health Consequences of COVID19 Infection in the French Rheumatic Musculoskeletal Diseases (RMD) Cohort
this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.